PET offers physicians and researchers insights into body dynamics that no other imaging options can, but it won’t work without tracer chemicals that can be linked to and highlight the reactions being investigated, and many current tracers are simply inadequate for what is needed. FluoroPharma, founded by Dr. David Elmaleh and led by a team with extensive radiopharmaceutical and medical technology experience, is researching new tracer chemicals to meet these needs.
Although there are millions of PET procedures performed in the U.S. annually, most are used in relation to cancer diagnosis. However, several factors have led to a shift in favor of using PET technology for the diagnosis of cardiac disease, which is a primary field of research for FluoroPharma. The company’s lead products, CardioPET and BFPET, are designed to improve patient diagnosis and management by evaluating various forms of cardiac disease at the cellular and molecular level. Molecular imaging is of significant value to patients with acute and chronic forms of coronary artery disease (CAD), providing benefit in the initial evaluation of patients with suspected but unproven CAD, and in those patients in whom a diagnosis of CAD has been established and information on prognosis or risk is required.
The market for novel cardiac PET tracing agents is expected to grow by at least 14% annually over the next five years, to approximately $900 million. It’s largely a wide-open market, other than one currently marketed branded cardiac PET tracer (which suffers from certain issues). FluoroPharma is focused on capitalizing on this fast growing market.
For more information, see the company website at www.FluoroPharma.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
